Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Home > Investor Relations > Press Releases

Press Releases

All Releases
View Summary Spectrum Pharmaceuticals Announces First Quarter 2016 Financial Results Teleconference and Webcast
Apr 28, 2016
PDF 14.5 KB Add to Briefcase
View Summary FDA Grants Orphan Drug Exclusivity to EVOMELA™ (melphalan) for Injection, Indicated for Multiple Myeloma
Apr 20, 2016
PDF 73.2 KB Add to Briefcase
View Summary FDA Grants Spectrum Pharmaceuticals Approval of EVOMELA™ (melphalan) for Injection
Mar 15, 2016
PDF 74.2 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Reports Fourth Quarter 2015 and Full Year 2015 Financial Results and Pipeline Update
Mar 9, 2016
PDF 45.5 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Initiates Phase 2 Breast Cancer Trial for Poziotinib, a Novel Pan-HER Inhibitor
Mar 7, 2016
PDF 16.6 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Announces Fourth Quarter and Full Year 2015 Financial Results Teleconference and Webcast
Mar 2, 2016
PDF 14.8 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals to Present Corporate Update at 2016 RBC Capital Markets' Global Healthcare Conference on February 24
Feb 22, 2016
PDF 13.6 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Announces FDA's Acceptance of NDA Filing for EOquin® (apaziquone for intravesical instillation)
Feb 19, 2016
PDF 12.7 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Begins Enrolling Patients in Registrational Trial of SPI-2012, a Novel, Long Acting G-CSF in Patients with Breast Cancer
Jan 29, 2016
PDF 20.6 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Signs a Strategic Partnership With Servier Canada
Jan 11, 2016
PDF 17.4 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Announces Agreement with FDA on the Special Protocol Assessment (SPA) for the Registrational Trial of SPI-2012, a Novel, Long Acting G-CSF in Patients with Breast Cancer
Dec 16, 2015
PDF 18.9 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Highlights Four Abstracts on SPI-2012 and Poziotinib at the San Antonio Breast Cancer Symposium (SABCS)
Dec 8, 2015
PDF 85.0 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals and Onxeo Announce Complete Response in 67% of Patients with Peripheral T-Cell Lymphoma in Combination of Belinostat (Beleodaq®) and Standard CHOP
Dec 6, 2015
PDF 95.7 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Highlights 18 Abstracts at the 57th Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida, December 5-8, 2015
Dec 4, 2015
PDF 73.3 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Submits Phase 2 Breast Cancer Protocol to FDA as Part of an Investigational New Drug (IND) Application for Poziotinib
Nov 20, 2015
PDF 61.7 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Divests Rights to ZEVALIN® (ibritumomab tiuxetan) in Japan and Select Other Ex-US Countries to Mundipharma
Nov 18, 2015
PDF 62.7 KB Add to Briefcase
View Summary Eagle Pharmaceuticals and Spectrum Pharmaceuticals Announce Co-Promotion Agreement
Nov 4, 2015
PDF 17.9 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Reports Third Quarter 2015 Financial Results and Pipeline Update
Nov 4, 2015
PDF 90.9 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Announces Third Quarter 2015 Financial Results Teleconference and Webcast
Nov 2, 2015
PDF 61.0 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Initiates Apaziquone Pivotal Trial for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC) Following SPA Agreement
Oct 26, 2015
PDF 64.3 KB Add to Briefcase
Showing 1-20 of 676 Page: 1 2 3 4 5 ... 34  Next 20
Add to Briefcase = add release to Briefcase

Back to top

Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

NASDAQ: SPPI

Price:
7.09
Change:
- 0.07
Day High:
7.25
Day Low:
7.03
Volume:
416,570
4:00 PM ET on Apr 29, 2016
Delayed at least 20 minutes.
Provided by eSignal.

Shareholder Tools

Print Email

Search IR